外科理论与实践

外科理论与实践 >

2023 , Vol. 28 >Issue 01: 1 - 6

DOI: https://doi.org/10.16139/j.1007-9610.2023.01.01

述评

胃癌外科综合治疗的若干进展与展望

展开
  • 上海交通大学医学院附属瑞金医院普外科 上海消化外科研究所 上海胃肿瘤重点实验室， 上海 200025

收稿日期: 2022-12-19

  网络出版日期: 2023-03-25

收起

Progress and prospect of surgical comprehensive treatment of gastric cancer

Expand
  • Department of General Surgery, Shanghai Institute of Digestive Surgery, Shanghai Key laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2022-12-19

  Online published: 2023-03-25

Fold

摘要

胃癌是国内、外常见恶性肿瘤，手术仍是治疗胃癌的主要方法。一系列临床研究改变了传统胃癌手术理念，避免盲目扩大手术切除范围。腹腔镜手术治疗早期和局部进展期胃癌的疗效并不劣于开腹手术。胃癌微创手术发展的关键是把握合理的手术指征，建立手术技术培训系统，以及优化成本与效益。理性认识胃癌扩大术脏器切除与保留脏器功能的关系。注重局部进展期胃癌围术期治疗的全程管理。并提倡晚期胃癌的术前转化治疗。对广泛转移晚期胃癌的姑息性切除术应慎之又慎，建议综合治疗，旨在延长病人生命。

关键词： 胃癌; 外科治疗; 围术期治疗

本文引用格式

朱正纲 . 胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023 , 28(01) : 1 -6 . DOI: 10.16139/j.1007-9610.2023.01.01

Abstract

Gastric cancer is one of the leading malignancies in China and in the world. Surgery is still the most important modality to cure gastric cancer. A series of clinical researches changed the traditional concept of surgery and avoided blindly expanding the scope of surgery. Laparoscopic surgery for both early and locally advanced gastric cancer achieved the same radical effect as open surgery. The key to further improve the efficacy of minimally invasive surgery is controlling indications, establishing a training system for surgical techniques and optimizing the relation between costs and benefits. The relationship between resection of organs and preservation of organ function should be balanced in the extended surgery for gastric cancer. Perioperative treatment of locally advanced gastric cancer would be advocated actively. Conversion therapy preoperatively for far-advanced gastric cancer is advocated. Palliative resection should be strictly controlled for the patients of far-advanced gastric cancer with extensive metastasis, and comprehensive treatment should be carried to prolong the life of patients.

Key words： Gastric cancer; Surgical treatment; Perioperative therapy

参考文献

[1] HARTGRINK H H, VAN DE VELDE C J, PUTTER H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial[J]. J Clin Oncol, 2004, 22(11):2069-2077.
[2] SONGUN I, PUTTER H, KRANENBARG E M, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5):439-449.
[3] SASAKO M, SANO T, YAMAMOTO S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomized controlled trial[J]. Lancet Oncol, 2006, 7(8):644-651.
[4] SASAKO M, SANO T, YAMAMOTO S, et al. D2 lympha-denectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5):453-462.
[5] SANO T, SASAKO M, MIZUSAWA J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma[J]. Ann Surg, 2017, 265(2):277-283.
[6] KUROKAWA Y, DOKI Y, MIZUSAWA J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7):460-468.
[7] KIM H H, HAN S U, KIM M C, et al. Effect of laparoscopic distal gastrectomy vs. open distal gastrectomy on long-term survival among patients with stage Ⅰgastric cancer: the KLASS-01 randomized clinical trial[J]. JAMA Oncol, 2019, 5(4):506-513.
[8] HYUNG W J, YANG H K, PARK Y K, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial[J]. J Clin Oncol, 2020, 38(28):3304-3313.
[9] KATAI H, MIZUSAWA J, KATAYAMA H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(2):142-151.
[10] YU J, HUANG C, SUN Y, et al. Effect of laparoscopic vs. open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20):1983-1992.
[11] LIU F, HUANG C, XU Z, et al. Morbidity and mortality of laparoscopic vs. open total gastrectomy for clinical stageⅠgastric cancer: the CLASS02 multicenter randomized clinical trial[J]. JAMA Oncol, 2020, 6(10):1590-1597.
[12] LI Z, SHAN F, YING X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2019, 154 (12):1093-1101.
[13] CHEN Q Y, XIE J W, ZHONG Q, et al. Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2020, 155(4):300-311.
[14] 姚学新, 严超, 燕敏, 等. 胃癌D_2根治术联合脾切除与否对疗效影响的比较研究[J]. 中华胃肠外科杂志, 2010, 13(2):111-114.
[14] YAO X X, YAN C, YAN M, et al. A comparative study on the efficacy of spleen-preserving modified D_2 radical gastrectomy and D_2 radical gastrectomy with splenectomy[J]. Chin J Gastrointest Surg, 2010, 13(2):111-114.
[15] 何晓生, 吴小剑, 汪建平, 等. 胃癌根治术腹主动脉旁淋巴结清扫安全性与有效性的Meta分析[J]. 中华胃肠外科杂志, 2010, 13(2):119-124.
[15] HE X S, WU X J, WANG J P, et al. Meta-analysis of safety and efficacy on paraaortic lymphadenectomy in gastric cancer[J]. Chin J Gastrointest Surg, 2010, 13(2):119-124.
[16] NAUM C, B?RL? R, MARICA D C, et al. In search of the optimal reconstruction method after total gastrectomy. is Roux-en-Y the best? A review of the randomized clinical trials[J]. Chirurgia, 2020, 115(1):12-22.
[17] ZHAO L, LING R, CHEN J, et al. Clinical outcomes of proximal gastrectomy versus total gastrectomy for proximal gastric cancer: a systematic review and meta-analysis[J]. Dig Surg, 2021, 38(1):1-13.
[18] CUNNINGHAM D, ALLUM W H, STENNING S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1):11-20.
[19] YCHOU M, BOIGE V, PIGNON J P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phaseⅢtrial[J]. J Clin Oncol, 2011, 29(13):1715-1721.
[20] AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184):1948-1957.
[21] KANG Y K, YOOK J H, PARK Y K, et al. PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer[J]. J Clin Oncol, 2021, 39(26):2903-2913.
[22] ZHANG X, LIANG H, LI Z, et al. Perioperative or post-operative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8):1081-1092.
[23] 丁学伟, 郑志超, 赵群, 等. 基于多中心真实世界数据的胃癌围手术期化疗患者生存分析[J]. 中华胃肠外科杂志, 2021, 24(5):403-412.
[23] DING X W, ZHENG Z C, ZHAO Q, et al. A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data[J]. Chin J Gastrointest Surg, 2021, 24(5):403-412.
[24] WANG F H, ZHANG X T, LI Y F, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J]. Cancer Commun (Lond), 2021, 41(8):747-795.
[25] GAO X, ZHANG Y, YUAN F, et al. Locally advanced gastric cancer: total iodine uptake to predict the response of primary lesion to neoadjuvant chemotherapy[J]. J Cancer Res Clin Oncol, 2018, 144(11):2207-2218.
[26] ZHANG Y, CHEN J, YUAN F, et al. Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor[J]. Diagn Interv Radiol, 2022, 28(5):388-395.
[27] CHEN Y, YUAN F, WANG L, et al. Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy[J]. Eur J Surg Oncol, 2022, 48(2):339-347.
[28] CHEN Y, XU W, LI Y L, et al. CT-based radiomics showing generalization to predict tumor regression grade for advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Front Oncol, 2022, 12:758863.
[29] YOSHIDA K, YAMAGUCHI K, OKUMURA N, et al. Is conversion therapy possible in stage Ⅳ gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2):329-338.
[30] 朱正纲. 晚期胃癌转化治疗的理念与临床意义[J]. 外科理论与实践, 2017, 22(1):1-4.
[30] ZHU Z G. Concept and clinical significance of conversion therapy for unresectable advanced gastric cancer[J]. J Surg Concepts Pract, 2017, 22(1):1-4.
[31] 朱正纲. 晚期胃癌转化治疗的难点、焦点与要点[J]. 外科理论与实践, 2019, 24(1):1-5.
[31] ZHU Z G. The difficulty and some focal points in conversion therapy for patients with far-advanced gastric cancer[J]. J Surg Concepts Pract, 2019, 24(1):1-5.
[32] HANAHAN D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1):31-46.
[33] YOSHIKAWA T, SASAKO M, YAMAMOTO S, et al. Phase Ⅱ study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer[J]. Br J Surg, 2009, 96(9):1015-1022.
[34] TSUBURAYA A, MIZUSAWA J, TANAKA Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J]. Br J Surg, 2014, 101(6):653-660.
[35] ZHANG K, CHEN L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases[J]. Ther Adv Med Oncol, 2020, 12: 1758835920904803
[36] 程向东, 季加孚. 胃癌卵巢转移诊断和治疗中国专家共识(2021版)[J]. 中国肿瘤, 2022, 31(2):81-87.
[36] CHENG X D, JI J F. The Chinese expert consensus on the diagnosis and treatment of ovarian metastasis from gastric cancer,2021[J]. China Cancer, 2022, 31(2):81-87.
[37] ISHIGAMI H, FUJIWARA Y, FUKUSHIMA R, et al. Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX GC trial[J]. J Clin Oncol, 2018, 36(19):1922-1929.
[38] YANG Z Y, YUAN F, LU S, et al. Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: a prospective phase Ⅱ study[J]. Front Oncol, 2022, 12:905922.
[39] 朱正纲. 胃癌腹膜转移转化性治疗的临床意义与实践要点[J]. 中华胃肠外科杂志, 2017, 20(10):1094-1098.
[39] ZHU Z G. Clinical significance and practice points of conversion therapy for gastric cancer with peritoneal metastasis[J]. Chin J Gastrointest Surg, 2017, 20(10):1094-1098.
[40] 朱正纲. 预防与治疗胃癌腹膜转移的若干关键问题[J]. 外科理论与实践, 2021, 26(1):1-6.
[40] ZHU Z G. Key issues in prevention and treatment of peritoneal metastatic gastric cancer[J]. J Surg Concepts Pract, 2021, 26(1):1-6.
Options
文章导航

/

〈 〉